MCID: THR004
MIFTS: 55

Thrombocytosis malady

Categories: Blood diseases

Aliases & Classifications for Thrombocytosis

Aliases & Descriptions for Thrombocytosis:

Name: Thrombocytosis 12 29 52 42 14 69
Thrombocythaemia 12
Thrombocythemia 14

Classifications:



External Ids:

Disease Ontology 12 DOID:2228
MeSH 42 D013922
NCIt 47 C35530
UMLS 69 C0836924

Summaries for Thrombocytosis

Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to essential thrombocythemia and poems syndrome. An important gene associated with Thrombocytosis is THPO (Thrombopoietin), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Anagrelide and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include myeloid, lung and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 71 Thrombocytosis (or thrombocythemia) is the presence of high platelet counts in the blood, and can be... more...

Related Diseases for Thrombocytosis

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
id Related Disease Score Top Affiliating Genes
1 essential thrombocythemia 32.8 F2 F3 SERPINC1
2 poems syndrome 29.7 CRP EPO THPO
3 neuropathy 29.6 CRP IL1B IL6 THPO
4 breast reconstruction 29.4 EPO IL1B IL6
5 bacterial meningitis 29.3 CRP F2 IL6
6 limb ischemia 29.3 CRP IL6 SELP
7 histiocytosis 29.2 CRP IL1B IL6
8 artery disease 29.1 CRP F2 F3
9 myocardial infarction 28.9 CRP F2 F3 IL1B IL6 SELP
10 myeloproliferative neoplasm 28.8 F2 F3 JAK2 MPL SELP SERPINC1
11 budd-chiari syndrome 28.7 CRP F2 F3 SELP SERPINC1
12 ischemic optic neuropathy 28.6 CRP F2 IL6 SELP SERPINC1
13 lupus erythematosus 28.5 CRP F3 IL6 SELP SERPINC1
14 hereditary thrombocytosis with transverse limb defect 11.8
15 thrombocythemia 1 11.4
16 erythromelalgia 11.1
17 polycythemia vera, somatic 10.9
18 thrombocythemia 3 10.9
19 thpo-related essential thrombocythemia 10.8
20 vitamin a embryopathy 10.3 EPO IL6
21 ectodermal dysplasia, ectrodactyly, and macular dystrophy 10.3 MPL THPO
22 coloboma of iris 10.3 CRP IL6
23 thrombocytopenia, congenital amegakaryocytic 10.2 IL3 MPL THPO
24 oculomotor nerve paralysis 10.2 IL1B IL6
25 spondylocostal dysostosis 2 10.2 EPO JAK2 MPL
26 acute infection of pinna 10.2 CRP F2
27 choledochal cyst 10.2 CSF2 IL3
28 pyloric stenosis, infantile hypertrophic, 4 10.2 EPO IL3 JAK2
29 common peroneal nerve lesion 10.2 IL1B IL6
30 queensland tick typhus 10.2 EPO IL3 JAK2
31 immunoglobulin g deficiency 10.2 IL1B IL6 THPO
32 cutaneous sclerosis 10.2 CRP IL6
33 laryngotracheoesophageal cleft type 2 10.2 CRP IL1B IL6
34 human immunodeficiency virus infectious disease 10.2 CRP IL1B IL6
35 refractory anemia 10.2
36 cytokine receptor deficiency 10.2 CSF2 IL3 THPO
37 benign neonatal seizures 10.2 CRP IL1B IL6
38 fiedler's myocarditis 10.2 F2 JAK2 THPO
39 central nervous system leiomyoma 10.2 CRP EPO IL6
40 acute panmyelosis with myelofibrosis 10.2 CSF2 EPO IL6
41 familial nephrotic syndrome 10.2 CRP EPO IL6
42 pancreas lymphoma 10.2 CRP IL1B IL6
43 blepharochalasis 10.2 CRP IL1B IL6
44 chordoid meningioma 10.2 CRP IL1B IL6
45 choroiditis 10.2 CRP IL1B IL6
46 rift valley fever 10.2 CRP IL1B IL6
47 supraumbilical midabdominal raphe and facial cavernous hemangiomas 10.2 F2 IL6
48 autoimmune disease of central nervous system 10.2 CRP F2 IL6
49 middle cerebral artery infarction 10.2 CSF2 IL3 THPO
50 infancy electroclinical syndrome 10.2 CRP IL1B IL6

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis

Symptoms & Phenotypes for Thrombocytosis

MGI Mouse Phenotypes related to Thrombocytosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 IL6 JAK2 LIF MPL SELP SERPINC1
2 hematopoietic system MP:0005397 10.21 CSF2 EPO F2 F3 IL1B IL6
3 cardiovascular system MP:0005385 10.18 CRP CSF2 EPO F2 F3 IL1B
4 immune system MP:0005387 10.18 EPO F2 F3 IL1B IL6 JAK2
5 embryo MP:0005380 10.06 F2 F3 JAK2 LIF MPL SERPINC1
6 integument MP:0010771 9.97 CSF2 EPO F2 F3 IL1B IL6
7 mortality/aging MP:0010768 9.9 CSF2 EPO F2 F3 IL1B IL6
8 liver/biliary system MP:0005370 9.73 EPO IL6 JAK2 LIF SELP SERPINC1
9 respiratory system MP:0005388 9.5 CSF2 EPO F2 F3 IL6 LIF
10 skeleton MP:0005390 9.23 IL6 JAK2 LIF SELP CSF2 EPO

Drugs & Therapeutics for Thrombocytosis

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2 127-07-1 3657
3 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
5 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
6
Lactitol Phase 4,Phase 2,Phase 3 585-86-4 3871
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
9 Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
10
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
12
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
13
Benzocaine Approved Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
16
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
17
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
19
Dalteparin Approved Phase 3 9041-08-1
20
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
21
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
22
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
23
Morphine Approved, Investigational Phase 3 57-27-2 5288826
24
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
25
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
26
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
27
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
28
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
29
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
30
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
31
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
32 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
33
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
34 Analgesics Phase 3,Phase 2,Phase 1
35 Anesthetics Phase 3
36 Anesthetics, Dissociative Phase 3
37 Anesthetics, General Phase 3
38 Anesthetics, Intravenous Phase 3
39 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
40 Excitatory Amino Acid Antagonists Phase 3
41 Excitatory Amino Acids Phase 3
42 Neurotransmitter Agents Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Antirheumatic Agents Phase 3,Phase 2,Phase 1
48 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
49 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 242)
id Name Status NCT ID Phase
1 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4
3 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4
4 INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis No longer available NCT01493414 Phase 4
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
6 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3
7 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3
8 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3
9 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3
10 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3
11 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3
12 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3
13 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3
14 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
19 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
20 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
21 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
22 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
24 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
25 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Recruiting NCT02577926 Phase 3
26 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Recruiting NCT02962388 Phase 2, Phase 3
27 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Active, not recruiting NCT01259856 Phase 3
28 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3
29 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3
30 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3
31 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3
32 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
33 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Not yet recruiting NCT02611973 Phase 3
34 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3
35 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3
36 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2
37 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2
38 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2
39 Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Unknown status NCT00949364 Phase 2
40 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2
41 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2
42 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2
43 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Completed NCT00413634 Phase 2
44 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2
45 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2
46 A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Completed NCT02125318 Phase 2
47 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT00935987 Phase 1, Phase 2
48 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT01236638 Phase 2
49 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2
50 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: thrombocytosis

Genetic Tests for Thrombocytosis

Genetic tests related to Thrombocytosis:

id Genetic test Affiliating Genes
1 Thrombocytosis 29

Anatomical Context for Thrombocytosis

MalaCards organs/tissues related to Thrombocytosis:

39
Myeloid, Lung, Bone, Bone Marrow, Heart, Liver, Breast

Publications for Thrombocytosis

Articles related to Thrombocytosis:

(show top 50) (show all 694)
id Title Authors Year
1
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 27714462 )
2017
2
Iron deficiency and thrombocytosis. ( 27870058 )
2017
3
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. ( 27734130 )
2017
4
Association between functional iron deficiency and reactive thrombocytosis in hospitalised patients: a case-control study. ( 27832554 )
2016
5
Hyper IgM Syndrome with low IgM and thrombocytosis: an unusual case of immunodeficiency. ( 27608476 )
2016
6
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia. ( 27256347 )
2016
7
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis. ( 27848258 )
2016
8
Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis. ( 27100794 )
2016
9
A Successful Mother and Neonate Outcome for a Woman with Essential Thrombocytosis and FV Leiden Heterozygosity. ( 27123352 )
2016
10
Genetic Analysis of Five Children With Essential Thrombocytosis Identifies Mutations in Cancer-Associated Genes With Roles in Transcriptional Regulation. ( 26992943 )
2016
11
Jack 2 negative essential thrombocytosis with portal vein thrombosis and portal cavernoma formation - A case report. ( 27728317 )
2016
12
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. ( 26874914 )
2016
13
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting with Severe Thrombocytosis without Leukocytosis. ( 27454200 )
2016
14
Paraneoplastic thrombocytosis in gastrointestinal cancer. ( 27136385 )
2016
15
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. ( 27479179 )
2016
16
Who is the culprit for the patient with acute myocardial infarction, plaque rupture or essential thrombocytosis? ( 26666344 )
2016
17
Outcomes after acute ischemic stroke in patients with thrombocytopenia or thrombocytosis. ( 26944147 )
2016
18
Embolic Stroke due to a Common Carotid Artery Thrombus in a Young Patient with Severe Iron-Deficiency Anemia without Thrombocytosis. ( 27752375 )
2016
19
Essential Thrombocytosis-Associated Thromboembolism in the Abdominal Aorta. ( 27734003 )
2016
20
Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis. ( 27812394 )
2016
21
Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. ( 26817451 )
2016
22
Association between secondary thrombocytosis and viral respiratory tract infections in children. ( 26965460 )
2016
23
Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. ( 27502272 )
2016
24
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations. ( 27994837 )
2016
25
Polycythemia and Thrombocytosis. ( 27866579 )
2016
26
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis. ( 27206953 )
2016
27
Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. ( 27716741 )
2016
28
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. ( 27139600 )
2016
29
Clinical significance of preoperative thrombocytosis in patients who underwent radical nephrectomy for nonmetastatic renal cell carcinoma. ( 27617313 )
2016
30
Poor Prognosis Significance of Pretreatment Thrombocytosis in Patients with Colorectal Cancer: a Meta-Analysis. ( 27797233 )
2016
31
Thrombocytosis in splenic trauma: In-hospital course and association with venous thromboembolism. ( 27451291 )
2016
32
Chronic Myeloid Leukemia: A Case of Extreme Thrombocytosis Causing Syncope and Myocardial Infarction. ( 27004153 )
2016
33
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. ( 27301073 )
2016
34
Acute Retroperitoneal Hematoma After Psoas Catheter Placement in a Patient with Myeloproliferative Thrombocytosis and Aspirin Therapy. ( 26779603 )
2016
35
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. ( 26967822 )
2016
36
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/ essential thrombocytosis myelofibrosis. ( 27354022 )
2016
37
How useful is thrombocytosis in predicting an underlying cancer in primary care? a systematic review. ( 27681942 )
2016
38
Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment. ( 27414763 )
2016
39
Pretreatment thrombocytosis predicts survival in colorectal cancer. ( 27255967 )
2016
40
Early recognition of intraventricular hemorrhage in the setting of thrombocytosis in the emergency department. ( 27307770 )
2016
41
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. ( 26608331 )
2016
42
An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. ( 28034873 )
2016
43
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma. ( 27532673 )
2016
44
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. ( 26754830 )
2016
45
Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker. ( 27733750 )
2016
46
Preoperative thrombocytosis predicts prognosis in stage II colorectal cancer patients. ( 27274508 )
2016
47
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients. ( 28009425 )
2016
48
Dengue fever associated with extreme reactive thrombocytosis ( 28078838 )
2016
49
Prognostic Significance of Pretreatment Thrombocytosis in Cervical Cancer Patients Treated With Definitive Radiotherapy. ( 26332391 )
2015
50
Thrombocytosis and Raised CRP Levels Predicts Advanced Stage in Esophageal Carcinoma. ( 26202142 )
2015

Variations for Thrombocytosis

Expression for Thrombocytosis

Search GEO for disease gene expression data for Thrombocytosis.

Pathways for Thrombocytosis

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 CSF2 EPO F2 IL1B IL3 IL6
2
Show member pathways
13.41 EPO F2 IL1B IL3 IL6 JAK2
3
Show member pathways
13.29 CSF2 IL1B IL3 IL6 JAK2 LIF
4
Show member pathways
13.28 CSF2 IL1B IL3 IL6 JAK2 LIF
5
Show member pathways
13.17 CSF2 IL1B IL3 IL6 JAK2 LIF
6
Show member pathways
13.1 CSF2 F2 F3 IL3 JAK2 MPL
7
Show member pathways
12.96 F2 IL3 IL6 JAK2 THPO
8 12.51 EPO IL3 IL6 JAK2
9
Show member pathways
12.51 F2 IL1B IL6 JAK2
10 12.46 IL1B IL3 JAK2 MPL
11
Show member pathways
12.24 CRP F2 IL1B IL6
12
Show member pathways
12.24 CSF2 IL1B IL6 JAK2
13
Show member pathways
12.07 IL1B IL3 IL6
14 11.98 IL3 IL6 LIF THPO
15 11.94 IL1B IL6 SELP
16 11.88 IL1B IL6 JAK2 LIF
17
Show member pathways
11.87 IL1B IL6 JAK2
18 11.87 IL1B IL3 IL6
19
Show member pathways
11.85 IL1B IL6 JAK2
20 11.84 CSF2 IL1B IL6 LIF
21
Show member pathways
11.82 F2 MPL THPO
22 11.81 CSF2 IL1B IL6
23
Show member pathways
11.79 CSF2 IL6 JAK2
24 11.79 F3 IL1B IL6 JAK2
25 11.77 CSF2 IL1B IL6
26
Show member pathways
11.75 CRP IL6 JAK2
27 11.74 CSF2 IL1B IL6
28 11.7 CSF2 EPO IL3 IL6 MPL THPO
29 11.68 CSF2 IL1B IL6
30 11.6 CSF2 IL1B IL6
31 11.6 EPO IL3 IL6 JAK2
32
Show member pathways
11.59 CSF2 IL1B IL6
33
Show member pathways
11.53 IL6 JAK2 LIF
34
Show member pathways
11.46 CSF2 EPO IL3 IL6 JAK2 LIF
35 11.45 IL1B IL6 SELP
36 11.43 EPO IL3 IL6
37 11.42 CSF2 IL1B IL6 LIF
38 11.42 CSF2 EPO IL1B IL3 IL6 THPO
39 11.34 CSF2 EPO IL1B IL3 IL6
40 11.2 CRP JAK2 MPL THPO
41 11.1 CSF2 IL1B IL3 IL6
42 11.09 CSF2 IL1B IL3 IL6 LIF
43 10.97 CRP IL6
44 10.85 IL1B IL6

GO Terms for Thrombocytosis

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CRP CSF2 EPO F2 F3 IL1B
2 extracellular space GO:0005615 9.4 CRP CSF2 EPO F2 F3 IL1B

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CSF2 IL1B IL3 IL6 LIF
2 inflammatory response GO:0006954 9.93 CRP IL1B IL6 SELP
3 MAPK cascade GO:0000165 9.89 CSF2 IL1B IL3 JAK2
4 positive regulation of cell proliferation GO:0008284 9.87 CSF2 EPO F2 IL3 IL6 JAK2
5 positive regulation of gene expression GO:0010628 9.85 CRP CSF2 IL1B IL6 LIF
6 blood coagulation GO:0007596 9.84 F2 F3 JAK2 SERPINC1
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.8 IL1B IL6 JAK2
8 response to lipopolysaccharide GO:0032496 9.8 EPO IL1B IL6 JAK2 SELP
9 positive regulation of protein kinase B signaling GO:0051897 9.77 F3 IL6 THPO
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 F2 JAK2 SELP
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 IL3 IL6 JAK2 LIF
12 hemostasis GO:0007599 9.72 F2 F3 SERPINC1
13 embryo implantation GO:0007566 9.7 EPO IL1B LIF
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 IL1B IL6 JAK2
15 positive regulation of DNA replication GO:0045740 9.67 CSF2 EPO IL3 IL6
16 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.65 IL6 JAK2 LIF
17 positive regulation of protein import into nucleus, translocation GO:0033160 9.62 IL6 JAK2
18 negative regulation of hormone secretion GO:0046888 9.61 IL6 LIF
19 tyrosine phosphorylation of STAT protein GO:0007260 9.61 JAK2 LIF
20 negative regulation of lipid storage GO:0010888 9.58 CRP IL6
21 tyrosine phosphorylation of Stat3 protein GO:0042503 9.56 JAK2 LIF
22 acute-phase response GO:0006953 9.56 CRP EPO F2 IL6
23 thrombopoietin-mediated signaling pathway GO:0038163 9.49 MPL THPO
24 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.46 CSF2 EPO IL3 JAK2
25 cytokine-mediated signaling pathway GO:0019221 9.43 F3 IL1B IL3 IL6 JAK2 MPL
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 CSF2 EPO IL3 IL6 JAK2 LIF

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 IL1B IL3 IL6 LIF THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 JAK2
3 interleukin-1 receptor binding GO:0005149 9.26 IL1B IL3
4 growth factor activity GO:0008083 9.1 CSF2 F2 IL3 IL6 LIF THPO

Sources for Thrombocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....